Japan opioid use disorder market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for opioid use disorders is anticipated to expand in the upcoming years as a result of factors such as an expansion of the patient base and the anticipated introduction of cutting-edge therapies by top firms like Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, AstraZeneca, and others. Some of the major key players in this market are AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Cerebral, Hikma Pharmaceuticals Plc., etc.
Japan Opioid Use Disorder Market is valued at around $182.9 Mn in 2022 and is projected to reach $415.4 Mn by 2030, exhibiting a CAGR of 10.8% during the forecast period 2023-2030.
Opioid Use Disorder (OUD) is a complicated disorder characterized by compulsive use of opioid medicines, despite a person's desire to stop using them or the fact that the drugs hurt their emotional and physical health. Buprenorphine, methadone, and naltrexone are three pharmacological groups used in pharmaceutical treatment. These are the only drug classes recognized by the American FDA. As the number of individuals suffering from chronic pain increases globally, there will undoubtedly be an increase in the number of prescriptions written for medicines, which usually contain opioids. However, after the patient has taken these opioid-based medications and the agony has subsided, the dependency or addiction to the drugs increases. This addiction has deadly consequences because an opioid overdose can cause death or a lifetime impairment of a person's typical psychological and physiological functioning. The market for opioid use disorders is anticipated to expand in the upcoming years as a result of factors such as an expansion of the patient base and the anticipated introduction of cutting-edge therapies by top firms like Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, AstraZeneca, and others. The major key players in this market are AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Cerebral, Hikma Pharmaceuticals PLC, NYC Health + Hospitals, Dr. Reddy, Indivior PLC, Mallinckrodt Pharmaceuticals, and Titan Pharmaceuticals, Inc.
Market Growth Drivers
Currently, the world's population suffers from a variety of severe and chronic illnesses, including cancer, cardiovascular ailments, and other maladies. To address these illnesses, patients take painkillers, typically opioids. Patients who utilize drugs frequently develop drug addictions. As a result of their abrupt discontinuation and growing dependence on certain medications, the patients could experience drug withdrawal symptoms. These may act as a driver for the opioid use disorder market. Another key aspect fueling the market rise is the increasing involvement of governmental and non-governmental groups in raising awareness about opioid overdose and its dangers.
Market Restraints
The market is expected to face challenges during the forecast period as a result of the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhea, constipation, respiratory problems, bone/joint pain, bladder pain, and cramping in the abdomen. In addition, when a drug reaction is strong, the patient may also experience depression and other psychological issues. Additionally, the U.S. FDA has issued a warning due to the hazards connected with these drugs, which has a negative effect on the drug class and decrease the uptake of pharmaceuticals for the treatment of OUD.
Key Player
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Product Type
By Receptor Binding
By Distribution Channels
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.